Psoriasis: from Pathogenesis to Targeted Therapies.

Détails

ID Serval
serval:BIB_54E377C5C063
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Psoriasis: from Pathogenesis to Targeted Therapies.
Périodique
Clinical reviews in allergy & immunology
Auteur⸱e⸱s
Conrad C., Gilliet M.
ISSN
1559-0267 (Electronic)
ISSN-L
1080-0549
Statut éditorial
Publié
Date de publication
02/2018
Peer-reviewed
Oui
Volume
54
Numéro
1
Pages
102-113
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Over the last decade, the management of psoriasis has witnessed a paradigm shift. Thanks to the increasing knowledge about the pathogenesis of psoriasis, targeted treatments with monoclonal antibodies have been developed. These antibodies, which target the pathogenic TNF/IL-23/IL-17-pathway, were shown to be safe and efficacious in the management of most patients with moderate to severe chronic plaque psoriasis. Recently, molecular and genetic studies in pustular and erythrodermic psoriasis have identified additional inflammatory pathways, providing evidence that psoriasis is a heterogeneous disease and highlighting the requirement for personalized disease characterization for treatment optimization. In this article, we will review these advances and provide an update on the currently available treatment arsenal. We discuss the efficacy and safety profile of these individual therapeutic agents and describe their use in special indications. We will also describe the current understanding of psoriasis as a systemic disease associated with multiple comorbidities and illustrate its impact in the management of psoriatic patients. Finally, we discuss ongoing therapeutic developments as well as unmet needs and future perspectives in the field of psoriasis.

Mots-clé
Biologicals, Inflammatory pathways, Pathogenesis, Psoriasis, Psoriasis comorbidities, TNFα inhibitors, Treatments
Pubmed
Web of science
Création de la notice
27/01/2018 13:09
Dernière modification de la notice
20/08/2019 14:09
Données d'usage